GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
== Function == This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. This enzyme participates in the Calvin cycle which is an autotrophic carbon fixation pathway.
Moreover, both the refractive index and the optical absorption are found to be dispersionless over a broad wavelength range from visible to near infrared. Finally, GO film offers flexible patterning capability by using the maskless DLW method, which reduces the manufacturing complexity and requirements. As a result, a novel ultrathin planar lens on a GO thin film has been realized recently using the DLW method. The distinct advantage of the GO flat lens is that phase modulation and amplitude modulation can be achieved simultaneously, which are attributed to the giant refractive index modulation and the variable linear optical absorption of GO during its reduction process, respectively. Due to the enhanced wavefront shaping capability, the lens thickness is pushed down to subwavelength scale (~200 nm), which is thinner than all current dielectric lenses (~ μm scale). The focusing intensities and the focal length can be controlled effectively by varying the laser powers and the lens sizes, respectively. By using an oil immersion high numerical aperture (NA) objective during DLW process, 300 nm fabrication feature size on GO film has been realized, and therefore the minimum lens size has been shrunk down to 4.6 μm in diameter, which is the smallest planar micro lens and can only be realized with metasurface by FIB. Thereafter, the focal length can be reduced to as small as 0.8 μm, which would potentially increase the numerical aperture (NA) and the focusing resolution.
=== Limitations === While the high-selectivity and tight-binding of RNA aptamers have generated interest in their use as pharmaceuticals, there are many problems which have prevented them from being successful in vivo. For one, without modifications RNA aptamers are degraded after being introduced into the body by nucleases in the span of a few minutes. Also, due to their small size, RNA aptamers can be removed from the bloodstream by the renal system. Because of their negative charge, RNA aptamers are additionally known to bind proteins in the bloodstream, leading to non-target tissue delivery and toxicity. Care must also be taken when isolating the RNA aptamers, as aptamers which contain repeated Cytosine-Phosphate-Guanine (CpG) sequences will cause immune system activation through the Toll-like receptor pathway. In order to combat some of the in vivo limitations of RNA aptamers, various modifications can be added to the nucleotides to aid in efficacy of the aptamer. For instance, a polyethylene glycol (PEG) moiety can be attached to increase the size of the aptamer, thereby preventing its removal from the bloodstream by the renal glomerulus. However, PEG has been implicated in allergic reactions during in vivo testing. Furthermore, modifications can be added to prevent nuclease degradation, such as a 2’ fluoro or amino group as well as a 3’ inverted thymidine. Additionally, the aptamer can be synthesized so that the ribose sugar is in the L-form instead of the D-form, further preventing nuclease recognition. Such aptamers are known as Spiegelmers.
== Food sources == Average daily intake varies between 120 and 240 μg/day, which is higher than dietary recommendations. Pork, lamb, and beef liver each have approximately 1.5 parts per million of molybdenum. Other significant dietary sources include green beans, eggs, sunflower seeds, wheat flour, lentils, cucumbers, and cereal grain.
Sources: en.wikipedia.org
== Cost == Monoclonal antibodies are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states", comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.
Then upon activation by ActA or VCA, the Arp complex is believed to undergo a major conformational change, bringing its two actin-related protein subunits near enough to each other to generate a new filament gate. Whether ATP hydrolysis may be required for nucleation and/or Y-branch release is a matter under active investigation.
Freud was the featured lecturer, and Jung spoke and received an honorary degree. The conference was planned by the psychologist G. Stanley Hall and included 27 distinguished psychiatrists, neurologists, and psychologists. It represented a watershed in the acceptance of psychoanalysis in North America. This forged welcome links between Jung and influential Americans. Jung returned to the United States the next year for a brief visit. In 1910, Freud proposed Jung, "his adopted eldest son, his crown prince, and successor," for the position of lifetime President of the newly formed International Psychoanalytical Association. However, after forceful objections from his Viennese colleagues, it was agreed Jung would be elected to serve a two-year term of office.
The Port of Dover is a cross-channel ferry, cruise terminal, maritime cargo and marina facility situated in Dover, Kent, south-east England. It is the nearest English port to France, at just 34 kilometres (21 mi) away, and is one of the world's busiest maritime passenger ports, with 11.7 million passengers, 2.6 million lorries, 2.2 million cars and motorcycles and 80,000 coaches passing through it in 2017, and with an annual turnover of £58.5 million a year. This compares with the nearby Channel Tunnel, the only fixed link between the island of Great Britain and the European mainland, which now handles an estimated 20 million passengers and 1.6 million trucks per year. The modern port facility features a large artificial harbour constructed behind stone piers and a defensive concrete breakwater. The port is divided into two main sections: the Eastern Docks serve as the main cross-channel ferry terminal, while the Western Docks contain a cruise ship terminal and a yacht marina along with cargo facilities. The Port of Dover has a long history and possesses several listed buildings and structures. The port is owned and operated by the Dover Harbour Board, a statutory corporation formed by royal charter in 1606 by King James I. Most of the board members of the Dover Harbour Board are appointees of the Department for Transport. The port has its own private police force, the Port of Dover Police. The current port traffic volumes and urban population categorise Dover as a Large-Port Town.
==== Chiral electrons and anomalies ==== This behavior is a direct result of graphene's chiral, massless Dirac electrons. In a magnetic field, their spectrum has a Landau level with energy precisely at the Dirac point. This level is a consequence of the Atiyah–Singer index theorem and is half-filled in neutral graphene, leading to the "+1/2" in the Hall conductivity. Bilayer graphene also shows the quantum Hall effect, but with only one of the two anomalies (i.e.
Sources: en.wikipedia.org
== Research == Frank's laboratory projects include an evaluation of MALDI-TOF identification of microorganisms and molecular methods for microbial identification. Frank's research collaboration with Juliane Bubeck Wardenburg in the departments of pediatrics and microbiology at the University of Chicago focused on the pathogenesis of Staphylococcus aureus pneumonia. Using microarray analysis of murine lung RNA, we examined the response of the host to a virulent Staphylococcal strain compared to a strain deficient in the alpha-toxin. We determined that the cellular immune response to infection was characterized by a prominent TH17 response to the wild-type pathogen. Investigation of the host-pathogen interaction and the pathogenesis of Staphylococcal lung injury will contribute to programs aimed at the development of novel therapeutic approaches for Staphylococcal disease.
=== Advantages === Advantages include low fragmentation: only a small amount of energy is transferred during the ionization process (compared to e.g. electron ionization), therefore fragmentation is suppressed and the obtained mass spectra are easily interpretable. No sample preparation is necessary: VOC-containing air and headspaces over liquids can be analyzed directly, in real time. A typical response time of 100 ms enables online monitoring. Absolute concentrations are obtained directly without previous calibration measurements. Due to the simple design and the low number of parts needed for a PTR-MS instrument, it can be built in into space saving and even mobile housings. PTR-MS operation requires only electric power and a small amount of distilled water. Unlike other techniques, no gas cylinders are needed for buffer gas or calibration standards.
The company reported that it secures raw material for paper cartons in cooperation with the World Wide Fund for Nature (WWF), the Global Forest and Trade Network (GFTN), and FSC, and that it strives to source polyethylene made from sugarcane from sustainable suppliers in Brazil. In 2010, 40 percent of Tetra Pak's carton supply was FSC-certified. Slowly, sectors where glass bottles have been paramount, like the wine and spirits industry, have begun to look at carton containers as a possible packaging product as the carbon footprint of a carton container is said to be about one-tenth of that of an equivalent glass bottle. Tetra Pak's sustainability work has gained recognition from industry and retailers alike. In 2010, it received the Swedish Forest Industries Climate Award for assuming global responsibility for the forests that provide its raw material. The recently introduced Tetra Recart has also been hailed by large retail groups like Sainsbury's as "the 21st Century alternative to canned foods" as the carton's rectangular shape makes transportation, storage, and distribution more efficient, taking up 21 percent less space and weighing two-thirds of a tin can of equivalent volume.
Opioids by themselves put older people at risk of respiratory depression and impaired ability to operate vehicles and other machinery. Combining these two drugs together not only increases a person's risk of the aforementioned adverse effects, but can increase a person's risk of overdose and death. Benzodiazepines are also the second leading cause of teen overdose death after fentanyl. They killed 152 people in 2021, less than a fifth of fentanyl's death toll. Hydrocodone was declared the most widely prescribed opioid between 2007 and 2016, and in 2015 the International Narcotics Control Board reported that greater than 98% of the hydrocodone consumed in the entire world was consumed by Americans.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.